A Phase 3, Randomized, Open-Label, Multicenter Study, to Compare T-Guard to Ruxolitinib for the Treatment of Patients with Grad III or IV Steroid Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)

Grant

Total Award Amount

  • 81132.00
  • Direct Costs

  • 62408.00
  • Sponsor Award Id

  • 2002
  • Contributor

  • Antonio Di Stasi M.D.   Investigator  
  • Donna Salzman M.D.   Investigator  
  • Lauren Shea   Investigator  
  • Omer Jamy   Principal Investigator